- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Asterias Biotherapeutics Gets Additional Clinical Site for Study
Asterias Biotherapeutics announced the addition of the Washington University School of Medicine in St. Louis as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1.
Asterias Biotherapeutics (NYSEMKT:AST) announced the addition of the Washington University School of Medicine in St. Louis as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1.
As quoted in the press release:
Washington University and its partner Barnes-Jewish Hospital have one of the largest clinical spine care practices in the United States. W. Zachary Ray, MD, Associate Professor of Neurological and Orthopedic Surgery at Washington University School of Medicine, will be the site’s principal investigator. Patients enrolled in the trial will receive the AST-OPC1 treatment during surgery at Barnes-Jewish.
“Given the study’s encouraging early results, we look forward to evaluating whether AST-OPC1 can advance treatment options for patients with severe cervical spinal cord injuries. This investigational therapy is an important contribution to our comprehensive program to treat spinal cord injuries here at Washington University and Barnes-Jewish,” said Dr. Ray.Barnes-Jewish Hospital’s Trauma Center was the first in Missouri to receive the American College of Surgeons (ACS) Level I verification, which is the highest national recognition possible from ACS.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.